13.23
Systeme mit modifizierter Wirkstofffreisetzung: ratenprogrammierte Systeme II
Ratenprogrammierte Systeme zur Wirkstofffreisetzung setzen Wirkstoffe kontrolliert frei, um therapeutische Wirkstoffkonzentrationen aufrechtzuerhalten…
Ratenprogrammierte Arzneimittelabgabesysteme können drei Designs verfolgen: Reservoir, Matrix oder Hybrid.
Reservoirsysteme umschließen den Arzneimittelkern in einem geschwindigkeitskontrollierenden Film oder einer Membran.
Nicht-schwellende Typen verwenden Ethylcellulose- und Polymethacrylatpolymere, um die Arzneimittelfreisetzung durch Dicke, Unlöslichkeit, langsame Auflösung oder Porosität zu steuern. Schwellungskontrollierte Typen verwenden häufig Polymere wie HPMC, um die Arzneimittelfreisetzung bis zur Membranhydratation zu verzögern.
Matrixsysteme betten das Medikament in ein freisetzungshemmendes Material ein.
Hydrophile Matrizen verwenden schwellbare Polymere wie HPMC, während hydrophobe Matrizen Wachse oder Ethylcellulose verwenden. Hydrophobe Matrizen können porös sein, wobei das Medikament in das Polymer eingemischt ist, oder nichtporös, wobei das Medikament in geschmolzenem Polymer dispergiert ist.
Hybridsysteme betten das Medikament in eine Matrix ein, die mit einem freisetzungsverzögernden Material beschichtet ist, das wiederum mit einem freisetzungskontrollierenden Polymer beschichtet wird. Dieses Design kombiniert die stetige Freisetzung von Reservoirsystemen mit der Haltbarkeit von Matrixgeräten und steuert so effektiv die Arzneimittelfreisetzung.
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.